Enhabit Inc

Enhabit Inc. insider sale: routine, price‑neutral trade by COA highlights investor buzz but strong clinical outcomes & compliance keep confidence high.

Enhabit insider trades reveal tax‑optimization, not a strategic shift—steady growth in home‑health/hospice services and a pending FDA‑approved pain drug could boost value.

Insider trades reveal Enhabit’s execs stay invested, underscoring confidence in its home‑health growth and strategic shift to value‑based, outpatient care.